Informations générales (source: ClinicalTrials.gov)
Phase 3b,Evaluation of MorphoTEP With the FDG Among Patients in Severe Sepsis of Unspecified Etiology
Interventional
Phase 3
Central Hospital, Nancy, France (Voir sur ClinicalTrials)
novembre 2008
octobre 2010
29 juin 2024
The objective of this pilot study is to estimate a procedure where the biological samples
routinely obtained at the site of suspected infection could be guided by the early
realization of a TEP with FDG coupled to scanner X, in patients hospitalized in ICU for
severe sepsis of unspecified etiology.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CHU; Central Hospital - 54000 - Nancy - France | sebastien md gibot, PhD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Patient hospitalized with severe sepsis
- Absence of infected site clearly identified after 48 hours of a conventional
diagnosis assessment or suspicion of one or more additional sites
- Indication of scanner X with injection
- Informed consent obtained
- Patient hospitalized with severe sepsis
- Absence of infected site clearly identified after 48 hours of a conventional
diagnosis assessment or suspicion of one or more additional sites
- Indication of scanner X with injection
- Informed consent obtained
- Age over 80
- Immunocompromised status
- Surgical intervention within the previous month
- Hemodynamic instability (defined by the use of more than 0.5µg/kg/min vasopressors)
- Severe hypoxia (defined by a PaO2/FiO2 ratio lower than 150)
- Pregnancy
- Patient already included in another protocol
- Anaphylaxis to Flucis